Cover Image
市場調查報告書

老齡化黃斑部病變 (AMD) 的主要7個國家市場預測

Age-related Macular Degeneration (AMD) Forecast in 7 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 356339
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
老齡化黃斑部病變 (AMD) 的主要7個國家市場預測 Age-related Macular Degeneration (AMD) Forecast in 7 Major Markets 2016-2026
出版日期: 2016年04月18日 內容資訊: 英文 40 Pages
簡介

本報告提供全球主要7個國家 (美國·法國·德國·義大利·西班牙·英國·日本) 市場上老齡化黃斑部病變之罹患情形調查,提供您得病數的變化與預測,年齡·症狀·病情·類型等各種類別的明細,並彙整疾病概要,危險因素,疾病診斷預後,主要的症狀和併發症等資料。

圖表

簡介

病因

危險因素和預防

疾病診斷

地區/各民族的差異

疾病預後和臨床過程

疾病相關的主要併發症/特徵

患者數定量化的手法

AMD的患病人數

AMD患者的特徵

  • 病情嚴重度和AMD的類型
  • 初期AMD
  • 後期AMD
  • 相關症狀
  • 滲出性AMD的相關症狀

簡稱

相關出版物

線上資料庫

參考文獻

附錄

目錄
Product Code: AMDN0010416

image1

Age-related macular degeneration (AMD or ARMD) or Age-related Maculopathy (ARM) is a condition that involves the degeneration and damage to the central area of the retina - the macula. It is currently a common cause of visual impairment in Western Europe. AMD is typically painless, and the loss of central vision usually occurs in both eyes but may progress at different speeds.

This report provides the current prevalent population for AMD across 7 Major Markets (USA, France, Germany, Italy, Spain, UK and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AMD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AMD include:

  • Serous retinal detachment
  • Haemorrhage
  • Charles Bonnet Syndrome
  • Depression
  • Reduced quality of life
  • Hypertension
  • Hypercholesterolaemia (abdominal obesity is a specific risk factor for males)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global AMD's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of AMD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AMD's prevalent population.
  • Identify sub-populations within AMD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AMD patients.

Coverage

FR, DE, IT, JP, ES, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

  • Additional data available on request

Top-Line Prevalence for Age-Related Macular Degeneration

Features of AMD Patients

  • Severity and Type of AMD
  • Early Type AMD
  • Late Type AMD
  • AMD Associated Conditions
  • Exudative AMD Associated Conditions

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables

  • AMD stages
  • Prevalence of AMD, total (000s)
  • Prevalence of AMD, males (000s)
  • Prevalence of AMD, females (000s)
  • Severity of AMD in patients, total (000s)
  • Early AMD by diameter (µm) of drusen present, total (000s)
  • Late AMD patients by type, total (000s)
  • Pigmentation abnormality in Early AMD patients, total (000s)
  • Type of CNV in Exudative AMD patients, total (000s)
  • Classic CNV location in Exudative AMD patients, total (000s)
  • Occult CNV location in Exudative AMD patients, total (000s)
  • Pattern of increased FAF at junctional zone in GA AMD patients, total (000s)
  • Prevalence of diabetes in AMD, total (000s)
  • Prevalence of hypertension in AMD, total (000s)
  • Prevalence of retinal detachment in Exudative AMD patients, total (000s)
  • Prevalence of subretinal haemorrhage in Exudative AMD patients, total (000s)
  • Prevalence of subretinal scarring in Exudative AMD patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of AMD by 5-yr age cohort, males (000s)
  • USA Prevalence of AMD by 5-yr age cohort, females (000s)
  • France Prevalence of AMD by 5-yr age cohort, males (000s)
  • France Prevalence of AMD by 5-yr age cohort, females (000s)
  • Germany Prevalence of AMD by 5-yr age cohort, males (000s)
  • Germany Prevalence of AMD by 5-yr age cohort, females (000s)
  • Italy Prevalence of AMD by 5-yr age cohort, males (000s)
  • Italy Prevalence of AMD by 5-yr age cohort, females (000s)
  • Spain Prevalence of AMD by 5-yr age cohort, males (000s)
  • Spain Prevalence of AMD by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of AMD by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of AMD by 5-yr age cohort, females (000s)
  • Japan Prevalence of AMD by 5-yr age cohort, males (000s)
  • Japan Prevalence of AMD by 5-yr age cohort, females (000s)
Back to Top